Cancer Trials Don’t Have To Fail 90% of the Time. Seriously.

11:00 AM - 12:00 PM (PDT), Wednesday, June 15, 2022

 With a 90% failure rate and tens of billions in lost R&D costs every year, there is no better characterization of the path to market for new cancer therapy than the proverbial “valley of death.” This panel brings to light the promise and pitfalls of bridging this valley with personalized medicine. The domain of personalized medicine (e.g., tumor biopsy tests) is often limited to bedside, while precision medicine (e.g., multi-omics) is favored on benchside. However, personalized medicine has considerable upstream potential in drug development, in- and out-licensing, and clinical trials design. While our discussion will be aimed at a general audience, it will be specific to immediately relevant aspects of drug R&D, lead and backup candidate selection, licensing, clinical trials, and regulatory processes. Participants will leave the discussion with a better understanding of how new tools and capabilities in personalized medicine can reduce the cost of bringing new cancer therapy to market.


 


 

Moderator
photo
CEO
CerFlux, Inc.
Speakers
photo
Manager, Strategic Industry Ventures
University of Texas, MD Anderson Cancer Center
photo
Board Member and Advisor
CerFlux, Inc.
photo
Sr. Director, Business Development
Johnson & Johnson
photo
Founding Director, Cancer Center
Aga Khan University